Washington Hospital Center, Washington, DC 20010, USA.
Am Heart J. 2010 Oct;160(4):595-604. doi: 10.1016/j.ahj.2010.06.007.
Antiplatelet therapy is a cornerstone of the management of patients with acute coronary syndromes or for those undergoing percutaneous coronary intervention. As the intricacies of platelet biology and mechanisms of thrombus formation are revealed, novel antiplatelet therapies have emerged. Bleeding risk, however, has grown in concert with more potent platelet inhibition. This article reviews platelet biology and receptors to provide a foundation for understanding of antiplatelelet therapy. It also highlights recent advances in antiplatelet therapy, with a focus on mechanisms of action, pharmacodynamic data, and the balance of thrombotic versus bleeding outcomes.
抗血小板治疗是急性冠状动脉综合征患者或经皮冠状动脉介入治疗患者治疗的基石。随着血小板生物学和血栓形成机制的复杂性逐渐被揭示，新型抗血小板治疗方法也不断涌现。然而，随着血小板抑制作用的增强，出血风险也随之增加。本文综述了血小板生物学和受体，为理解抗血小板治疗提供了基础。本文还重点介绍了抗血小板治疗的最新进展，包括作用机制、药效学数据以及血栓形成与出血结局的平衡。
